Fueling the Future of Regeneration: Applied StemCell Launches hiEX iPSC Exosomes

Published: 30 Jun 2025

Author: Precedence Research

Share :

Applied StemCell is a leading-edge provider of stem cell and gene editing products, and it announced a new product today, hiEXTM Research iPSC Exosomes. This PI product has been designed for research use only to assist scientists in examining the wide regenerative capabilities of exosomes generated through induced pluripotent stem cells (iPSCs). Where direct benefit is now possible in high-tech areas, such as wound healing, aging, and neural regeneration, by using highly pure human iPSCs directed in exosomes. The hiEX 0 Research iPSC Exosomes places researchers one step closer to the goal of cell-free therapeutics.

Driven by Applied StemCell's own proprietary TARGATT large knock-in technology, the source cell line can be engineered to deliver exosomes with a given therapeutic or experimental payload. This is a cost-effective, non-donor-derived, flexible, and reproducible solution that scientists use to conduct the next generation of translational research and discovery.

Exosomes have become one of the most promising vehicles for delivering therapeutic molecules, eliminating the risks associated with whole-cell therapy. In comparison, donor-derived exosomes may be variable in terms of quality and are associated with the risk of immunogenicity. iPSC-derived exosomes have a more defined composition and are better characterized. The increased standardization enhances the replicability of experimental results and the scale required for success in translation. The hiEX platform by Applied StemCell capitalizes on these advantages, is associated with a consistent quality of research from lot to lot and is expected to support regulatory compliance in the downstream sale of the product.

This recent introduction is an addition to the Applied StemCell tradition of providing researchers with the tools that can make a breakthrough. The company has ceaselessly been distinguished by its innovative gene-editing services, along with CRISPR and engineered cell lines. With the introduction of the hiEXTM exosome product, the company has added an additional powerhouse cell-free solution to its product portfolio, further cementing its reputation as an end-to-end facilitator of regenerative research. From stem cells to smart vesicles, Applied StemCell is helping to shape the future of the biomedical field.

CEO and Executive Statements

Dr. Ruby Tsai, CEO of Applied StemCell, shared her perspective on the company’s vision

“Exosomes offer exciting possibilities as cell-free tools in regenerative medicine. Our hiEX™ iPSC Exosomes give researchers a dependable and well-defined starting point for exploring those possibilities.”